International journal of radiation oncology, biology, physics
Treatment With Stereotactic Ablative Radiotherapy for patients with Up to 5 Oligometastatic cancer lesions: Long-Term Outcomes of the Nonrandomized Population-Based Phase 2 SABR-5 Clinical Trial.
Curtis Leclerc, Sarah Baker, Will Jiang, Benjamin Mou, Mitchell Liu, Alana Bergman, Devin Schellenberg, Abraham Alexander, Hannah Carolan, Siavesh Atrchian, Nick Chng, Quinn Matthews, Alexander Benny, Scott Tyldesley, Robert Olson
Published: 202610.1016/j.ijrobp.2026.01.012
Abstract
PURPOSE/OBJECTIVE(S): The use of SABR for oligometastatic cancer is expanding, but prospective long-term survival data are limited. This study reports long-term secondary outcomes of overall survival (OS), progression-free survival (PFS), local contr…
Preview only. Read the full abstract at the source